Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy

被引:17
|
作者
Strober, B. E. [1 ,2 ]
Poulin, Y. [3 ]
Teller, C. [4 ]
Wang, Y. [5 ]
Williams, D. A. [5 ]
Goldblum, O. M. [5 ]
机构
[1] Univ Connecticut Hlth Ctr, Dept Dermatol, Farmington, CT 06030 USA
[2] Prob Med Res Inc, Waterloo, ON, Canada
[3] Univ Laval, Ctr Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[4] Bellaire Dermatol Associates, Bellaire, TX USA
[5] AbbVie Inc, N Chicago, IL USA
关键词
RISK;
D O I
10.1111/jdv.12372
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundPsoriasis treatment can lower levels of the inflammatory biomarker C-reactive protein (CRP). ObjectiveEvaluate CRP changes in patients with chronic plaque psoriasis who switched to adalimumab following suboptimal response to previous therapies. MethodsC-reactive protein was measured at screening and after 16weeks of adalimumab treatment following discontinuation of previous therapies: etanercept (substudy E; n=77), methotrexate (substudy M; n=38) or narrow-band ultraviolet B phototherapy (substudy P; n=27). Associations of CRP with baseline characteristics and efficacy measures were evaluated. ResultsMedian CRP change at the final visit was -0.3mg/L overall and -0.4, -0.3 and -0.3mg/L in substudies E, M and P respectively. Clinical response [Physician Global Assessment (PGA) clear' or minimal'] was associated with greater CRP reductions vs. no response (PGA mild' or worse) overall (-0.4 vs. -0.3mg/L) and in substudies E (-0.4 vs. -0.1mg/L) and M (-0.5 vs. -0.2mg/L), but not P (-0.1 vs. -0.4mg/L). CRP decreases were, respectively, -0.4 and -0.3mg/L in patients with and without a history of psoriatic arthritis and -0.1, -0.3 and -0.6mg/L in normal weight, overweight and obese patients, respectively. CRP decreases after 16weeks correlated positively (=0.004) with percentage change in Psoriasis Area and Severity Index (PASI; P=0.0398) and negatively (=-0.360) with baseline CRP (P<0.0001). ConclusionC-reactive protein levels decreased during adalimumab therapy in patients with psoriasis who experienced suboptimal response to previous therapies. Clinical response was associated with greater CRP reductions overall and in substudies E and M, but not P. CRP reductions correlated with percentage reductions in PASI.
引用
收藏
页码:1701 / 1706
页数:6
相关论文
共 50 条
  • [31] C-reactive protein levels and survival in patients with moderate to very severe COPD
    de Torres, Juan P.
    Pinto-Plata, Victor
    Casanova, Ciro
    Mullerova, Hanna
    Cordoba-Lanus, Elizabeth
    Muros de Fuentes, Mercedes
    Aguirre-Jaime, Armando
    Celli, Bartolome R.
    CHEST, 2008, 133 (06) : 1336 - 1343
  • [32] High-sensitivity C-Reactive Protein Response to Adalimumab in Hidradenitis Suppurativa Patients
    Zouboulis, C. D.
    Adams, D. A.
    Gu, Y.
    Goldblum, O. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S67 - S67
  • [33] C-reactive protein predicts treatment response to adalimumab (HUMIRA®) in patients with rheumatoid arthritis
    Cohen, SB
    Kavanaugh, AF
    Emery, P
    Keystone, EC
    Segurado, OG
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 437 - 437
  • [34] High-sensitivity c-reactive protein response to adalimumab in hidradenitis suppurativa patients
    Zouboulis, C. C.
    Adams, D. A.
    Gu, Y.
    Goldblum, O. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S88 - S88
  • [35] Secukinumab reduces C-reactive protein levels in patients with moderate to severe plaque psoriasis: Result of a regimen-finding study
    Strober, Bruce
    Guettner, Achim
    Sigurgeirrson, Bardur
    Papavassilis, Charis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB212 - AB212
  • [36] Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial
    Thaci, D.
    Galimberti, R.
    Amaya-Guerra, M.
    Rosenbach, T.
    Robertson, D.
    Pedersen, R.
    Yang, S.
    Kuligowski, M.
    Boggs, R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (07) : 900 - 906
  • [37] Maintenance of response in patients with moderate-to-severe plaque psoriasis treated with mirikizumab and retreatment response after loss of efficacy
    Reich, Kristian
    Papp, Kim A.
    Leonardi, Craig
    Menter, Alan
    Li, Joanne
    Tuttle, Jay
    Patel, Dipak
    Arora, Vipin
    Friedrich, Stuart
    Bissonnette, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB236 - AB236
  • [38] IMPROVED QUALITY OF LIFE AND PRODUCTIVITY IN PATIENTS WITH MODERATE OR SEVERE RHEUMATOID ARTHRITIS ACTIVELY SWITCHED TO TREATMENT WITH INFLIXIMAB FROM ADALIMUMAB OR ETANERCEPT THERAPY
    Fleischmann, Roy
    Bolce, Rebecca
    Wang, Jianping
    Ingham, Mike
    Dehoratius, Ralph
    Decktor, Dennis
    RHEUMATOLOGY, 2012, 51 : 138 - 138
  • [39] Hemoglobin Levels and Serum C-Reactive Protein in Patients With Moderate to Severe Hidradenitis Suppurativa
    Huang, Christina M.
    Lowes, Michelle A.
    Cserti, Christine
    Alavi, Afsaneh
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2019, 23 (05) : 501 - 506
  • [40] IMPACT OF THE DISCORDANCE BETWEEN C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION RATE ON CLINICAL RESPONSE TO COMBINATION ETANERCEPT-METHOTREXATE THERAPY IN RHEUMATOID ARTHRITIS
    Fleischmann, R. M.
    Szumski, A.
    Jones, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 205 - 206